TheraRadar
← Back
Data updated: Sep 20, 2026

Pfizer

PFE Big Pharma
OncologyInfectious DiseaseImmunology Execution: Good

Global pharmaceutical leader with blockbuster franchises in vaccines (Prevnar, Comirnaty), cardiovascular (Eliquis), and oncology. Known for rapid COVID-19 vaccine development and strategic acquisitions including Seagen.

$58.5B
Revenue (2024)
$145.0B
Market Cap
-
Trials
10
New Drugs (2yr)
Modality:
81 Small Molecules 12 Biologics

FDA Novel Drug Designations

(2017-2024)
14 Novel 3 First-in-Class 7 Orphan 4 Breakthrough 2 Accelerated 8 Priority Review 2 Fast Track
See 14 novel approvals →
2024 HYMPAVZI (MARSTACIMAB-HNCQ) First-in-Class · Orphan
2023 LITFULO (RITLECITINIB TOSYLATE)
2023 PAXLOVID (COPACKAGED) (NIRMATRELVIR) First-in-Class · Priority Review · Fast Track
2023 ELREXFIO (ELRANATAMAB) Orphan · Breakthrough · Priority Review · Accelerated · Fast Track
2023 NGENLA (SOMATROGON-GHLA) Orphan
2023 ZAVZPRET (ZAVEGEPANT HYDROCHLORIDE)
2023 VELSIPITY (ETRASIMOD ARGININE)
2022 CIBINQO (ABROCITINIB) Breakthrough · Priority Review
2020 NURTEC ODT (RIMEGEPANT SULFATE)
2018 VIZIMPRO (DACOMITINIB) Orphan · Priority Review
2018 TALZENNA (TALAZOPARIB TOSYLATE) Priority Review
2018 LORBRENA (LORLATINIB) Orphan · Breakthrough · Priority Review · Accelerated
2018 DAURISMO (GLASDEGIB MALEATE) Orphan · Priority Review
2017 BESPONSA (INOTUZUMAB OZOGAMICIN) First-in-Class · Orphan · Breakthrough · Priority Review

Pfizer at a Glance

  • Leading 42 drug targets across portfolio
  • Fast trial execution (11 months median completion)

Pfizer's Recent FDA Approvals

Pfizer secured 10 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

SODIUM BICARBONATE NDA
2026-08-14
sodium bicarbonate
Metabolic Acidosis
SODIUM BICARBONATE NDA
2026-07-09
sodium bicarbonate
Metabolic Acidosis
EPINEPHRINE NDA
2026-03-30
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
BENDAMUSTINE HYDROCHLORIDE NDA
2025-07-03
bendamustine hydrochloride
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
EPINEPHRINE NDA
2025-03-13
epinephrine
1 INDICATIONS AND USAGE Epinephrine is a non-selective alpha and beta adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine Injection USP, 1 mg/10 mL (0.1 mg/mL) is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections
HYMPAVZI BLA
2024-10-11
marstacimab-hncq
Hemophilia A

Pfizer's Therapeutic Areas

Pfizer's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 12 biologic and 81 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 36%
29 drugs Phase 3: 76 Phase 2: 101 Phase 1: 201
Infectious Disease 21%
27 drugs Phase 3: 51 Phase 2: 51 Phase 1: 52
Immunology 19%
12 drugs Phase 3: 53 Phase 2: 63 Phase 1: 50
Neurology 13%
8 drugs Phase 3: 38 Phase 2: 30 Phase 1: 45
Dermatology 11%
18 drugs Phase 3: 25 Phase 2: 23 Phase 1: 16

Pfizer Pipeline Snapshot

Pfizer has 875 active clinical programs from ClinicalTrials.gov — 243 Phase 3, 268 Phase 2 and 364 Phase 1.

243
Phase 3
268
Phase 2
364
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2026
Avelumab
Advanced Malignancies
Estimated · fresh NCT05059522
Q4 2026
Rimegepant
Migraine
Estimated · fresh NCT06616194
Q4 2026
Rimegepant
Menstrual Migraine
Estimated · fresh NCT06641466
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • IBRANCE leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 257/390 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges